Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Rifaximin tablets (adults) - selected U.S. labeling
Product / population
Adult oral rifaximin tablets for the labeled traveler-diarrhea, hepatic-encephalopathy-recurrence and IBS-D uses. Not rifampin or rifabutin.
Renal method
No renal pharmacokinetic study or numeric adjustment algorithm in the selected label.
Source revision
Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved
2026-09-05
Local review status
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Official
Rifaximin tablets (adults) - selected U.S. labeling
U.S. product labeling / DailyMed · Adult oral rifaximin tablets for the labeled traveler-diarrhea, hepatic-encephalopathy-recurrence and IBS-D uses. Not rifampin or rifabutin.
Renal method: No renal pharmacokinetic study or numeric adjustment algorithm in the selected label. Source date: Label revision date not separately recorded; retrieval date is not the revision date. Retrieved: 2026-09-05
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Labeled basic dosing
Indication
Adult oral schedule
Noninvasive E. coli travelers' diarrhea
200 mg three times daily for 3 days
Reduce overt hepatic encephalopathy recurrence
550 mg twice daily
IBS with diarrhea
550 mg three times daily for 14 days; up to two repeat courses for recurrence
The label states that renal-impairment pharmacokinetics have not been studied. It does not establish a numeric renal or dialysis regimen. Do not reclassify this as a label-proven no-adjustment statement.
Do not use the traveler-diarrhea regimen for fever, bloody stool or suspected invasive pathogens. Severe hepatic disease increases exposure; review P-glycoprotein inhibitors.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.